The latest price target for Palvella Therapeutics (NASDAQ:PVLA) was reported by Scotiabank on March 7, 2025. The analyst firm set a price target for $50.00 expecting PVLA to rise to within 12 months (a possible 106.19% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Palvella Therapeutics (NASDAQ:PVLA) was provided by Scotiabank, and Palvella Therapeutics initiated their sector outperform rating.

There is no last upgrade for Palvella Therapeutics

There is no last downgrade for Palvella Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Palvella Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Palvella Therapeutics was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.

While ratings are subjective and will change, the latest Palvella Therapeutics (PVLA) rating was a initiated with a price target of $0.00 to $50.00. The current price Palvella Therapeutics (PVLA) is trading at is $24.25, which is within the analyst’s predicted range.